FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588943900> ?p ?o ?g. }

• W2588943900 endingPage "292" @default.
• W2588943900 startingPage "292" @default.
• W2588943900 abstract "292 Background: Conventional transcatheter arterial chemoembolization (TACE) using with ethiodized oil mixed with epirubicin or doxorubicin hydrochloride mainly has been widely adapted for intermediate-stage hepatocellular carcinoma (HCC). However, cisplatin has stronger effect for HCC than epirubicin and in the recent years cisplatin powder was commercially available in Japan and then we can use cisplatin powder mixed with ethiodized oil for HCC. We conducted a phase II study to assess the safety and efficacy of segmental or subsegmental (Seg/Subseg) TACE using a suspension of cisplatin powder mixed with ethiodized oil for unresectable HCC. Methods: Twenty patients with single-nodule HCC that was not indicated for surgical treatment or local ablation therapy were enrolled in this study. Seg/Subseg-TACE was performed by using a 2-F tip microcatheter at a distal portion of the subsegmental artery supplying the tumor. Subsequently, the feeding artery was embolized with gelatin sponge particles. The suspension was prepared by mixing 100 mg of cisplatin powder with 10 ml of ethiodized oil. Primary endpoint of this phase II trial was 2-year local disease free survival (DFS); secondary endpoints evaluated were the safety, time to progression (TTP), and 2-year overall survival (OS) rate. Results: A total of 20 patients (male 15, female 5; mean age 72.4, range 62-83; Child Pugh's A 20) were treated single nodule HCC with Seg/subseg TACE. Median tumor size was 2.6cm (range1.2-5.0cm). The 2-year local DFS was 63.2 %. The following grade 3 or 4 toxicities were observed: platelets reduction 5%, aspartate transaminase elevation 55%, alanine transaminase elevation 40% and alkaline phosphatase elevation 5%. The median TTP was 17.6 months (95%CI, 5.25 to 29.9) and the 2-year OS rate was 94.7%. Conclusions: This phase II study demonstrates that segmental or subsegmental transcatheter arterial chemoembolization using a suspension of cisplatin powder mixed with ethiodized oil is well tolerable, and may achieve significant local tumor control and prolong survival. Further clinical trials are warranted. No significant financial relationships to disclose." @default.
• W2588943900 created "2017-02-24" @default.
• W2588943900 creator A5002830709 @default.
• W2588943900 creator A5017442524 @default.
• W2588943900 creator A5027657262 @default.
• W2588943900 creator A5041636298 @default.
• W2588943900 creator A5050690813 @default.
• W2588943900 creator A5053212032 @default.
• W2588943900 creator A5054317050 @default.
• W2588943900 creator A5064855343 @default.
• W2588943900 creator A5080835756 @default.
• W2588943900 creator A5081245780 @default.
• W2588943900 date "2011-02-01" @default.
• W2588943900 modified "2023-09-25" @default.
• W2588943900 title "Phase II study of segmental transcatheter arterial chemoembolization using ethiodized oil mixed with cisplatin powder for unresectable hepatocellular carcinoma." @default.
• W2588943900 doi "https://doi.org/10.1200/jco.2011.29.4_suppl.292" @default.
• W2588943900 hasPublicationYear "2011" @default.
• W2588943900 type Work @default.
• W2588943900 sameAs 2588943900 @default.
• W2588943900 citedByCount "0" @default.
• W2588943900 crossrefType "journal-article" @default.
• W2588943900 hasAuthorship W2588943900A5002830709 @default.
• W2588943900 hasAuthorship W2588943900A5017442524 @default.
• W2588943900 hasAuthorship W2588943900A5027657262 @default.
• W2588943900 hasAuthorship W2588943900A5041636298 @default.
• W2588943900 hasAuthorship W2588943900A5050690813 @default.
• W2588943900 hasAuthorship W2588943900A5053212032 @default.
• W2588943900 hasAuthorship W2588943900A5054317050 @default.
• W2588943900 hasAuthorship W2588943900A5064855343 @default.
• W2588943900 hasAuthorship W2588943900A5080835756 @default.
• W2588943900 hasAuthorship W2588943900A5081245780 @default.
• W2588943900 hasConcept C126322002 @default.
• W2588943900 hasConcept C126838900 @default.
• W2588943900 hasConcept C126894567 @default.
• W2588943900 hasConcept C203092338 @default.
• W2588943900 hasConcept C2776694085 @default.
• W2588943900 hasConcept C2776755627 @default.
• W2588943900 hasConcept C2778019345 @default.
• W2588943900 hasConcept C2778239845 @default.
• W2588943900 hasConcept C2778455285 @default.
• W2588943900 hasConcept C2780835546 @default.
• W2588943900 hasConcept C535046627 @default.
• W2588943900 hasConcept C71924100 @default.
• W2588943900 hasConceptScore W2588943900C126322002 @default.
• W2588943900 hasConceptScore W2588943900C126838900 @default.
• W2588943900 hasConceptScore W2588943900C126894567 @default.
• W2588943900 hasConceptScore W2588943900C203092338 @default.
• W2588943900 hasConceptScore W2588943900C2776694085 @default.
• W2588943900 hasConceptScore W2588943900C2776755627 @default.
• W2588943900 hasConceptScore W2588943900C2778019345 @default.
• W2588943900 hasConceptScore W2588943900C2778239845 @default.
• W2588943900 hasConceptScore W2588943900C2778455285 @default.
• W2588943900 hasConceptScore W2588943900C2780835546 @default.
• W2588943900 hasConceptScore W2588943900C535046627 @default.
• W2588943900 hasConceptScore W2588943900C71924100 @default.
• W2588943900 hasIssue "4_suppl" @default.
• W2588943900 hasLocation W25889439001 @default.
• W2588943900 hasOpenAccess W2588943900 @default.
• W2588943900 hasPrimaryLocation W25889439001 @default.
• W2588943900 hasRelatedWork W2007112825 @default.
• W2588943900 hasRelatedWork W2017688048 @default.
• W2588943900 hasRelatedWork W2096546425 @default.
• W2588943900 hasRelatedWork W2132261997 @default.
• W2588943900 hasRelatedWork W2385537267 @default.
• W2588943900 hasRelatedWork W2386253513 @default.
• W2588943900 hasRelatedWork W2401483455 @default.
• W2588943900 hasRelatedWork W3029401434 @default.
• W2588943900 hasRelatedWork W3148549675 @default.
• W2588943900 hasRelatedWork W3201340738 @default.
• W2588943900 hasVolume "29" @default.
• W2588943900 isParatext "false" @default.
• W2588943900 isRetracted "false" @default.
• W2588943900 magId "2588943900" @default.
• W2588943900 workType "article" @default.